Friede Tim, Kieser Meinhard
Novartis Pharma AG, Biostatistics and Statistical Reporting, Basel, Switzerland.
Biom J. 2006 Aug;48(4):537-55. doi: 10.1002/bimj.200510238.
The adequacy of sample size is important to clinical trials. In the planning phase of a trial, however, the investigators are often quite uncertain about the sizes of parameters which are needed for sample size calculations. A solution to this problem is mid-course recalculation of the sample size during the ongoing trial. In internal pilot study designs, nuisance parameters are estimated on the basis of interim data and the sample size is adjusted accordingly. This review attempts to give an overview on the available methods. It is written not only for biometricians who are already familar with the the topic and wish to update their knowledge but also for users new to the subject.
样本量的充足性对临床试验很重要。然而,在试验的规划阶段,研究人员往往对样本量计算所需的参数大小相当不确定。解决这个问题的一个办法是在正在进行的试验过程中对样本量进行中期重新计算。在内部预试验设计中,根据中期数据估计干扰参数,并相应地调整样本量。本综述试图对可用方法进行概述。它不仅是为已经熟悉该主题并希望更新知识的生物统计学家编写的,也是为该主题的新手用户编写的。